Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


Histogram analysis of en face scattering coefficient map predicts malignancy in human ovarian tissue.

Zeng Y, Nandy S, Rao B, Li S, Hagemann AR, Kuroki LK, McCourt C, Mutch DG, Powell MA, Hagemann IS, Zhu Q.

J Biophotonics. 2019 Jul 14:e201900115. doi: 10.1002/jbio.201900115. [Epub ahead of print]


Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck-Noia H, Hagemann IS, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.


Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US.

Nandy S, Mostafa A, Hagemann IS, Powell MA, Amidi E, Robinson K, Mutch DG, Siegel C, Zhu Q.

Radiology. 2018 Dec;289(3):740-747. doi: 10.1148/radiol.2018180666. Epub 2018 Sep 11.


Quantitative multispectral ex vivo optical evaluation of human ovarian tissue using spatial frequency domain imaging.

Nandy S, Hagemann IS, Powell MA, Siegel C, Zhu Q.

Biomed Opt Express. 2018 Apr 30;9(5):2451-2456. doi: 10.1364/BOE.9.002451. eCollection 2018 May 1.


p16 Immunohistochemistry Is Not Always Required For Accurate Diagnosis of Grade 2 Squamous Intraepithelial Lesions.

Sun L, Zhang L, Krigman HR, Hagemann IS.

J Low Genit Tract Dis. 2018 Apr;22(2):104-109. doi: 10.1097/LGT.0000000000000370.


Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case.

Dandulakis MG, Mattis AJ, Hagemann AR, Hagemann IS.

Gynecol Oncol Rep. 2018 Jan 2;23:16-19. doi: 10.1016/j.gore.2017.12.006. eCollection 2018 Feb.


Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women.

Toriola AT, Dang HX, Hagemann IS, Appleton CM, Colditz GA, Luo J, Maher CA.

Oncotarget. 2017 May 17;8(43):73787-73792. doi: 10.18632/oncotarget.17909. eCollection 2017 Sep 26.


Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.

Lee PJ, McNulty S, Duncavage EJ, Heusel JW, Hagemann IS.

Int J Gynecol Pathol. 2018 Nov;37(6):581-589. doi: 10.1097/PGP.0000000000000459.


Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2017 Dec;16(12):2881-2891. doi: 10.1158/1535-7163.MCT-17-0587. Epub 2017 Sep 13.


Multiple Myeloma Presenting as Massive Amyloid Deposition in a Parathyroid Gland Associated with Amyloid Goiter: A Medullary Thyroid Carcinoma Mimic on Intra-operative Frozen Section.

Hill K, Diaz J, Hagemann IS, Chernock RD.

Head Neck Pathol. 2018 Jun;12(2):269-273. doi: 10.1007/s12105-017-0853-7. Epub 2017 Sep 6.


A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.


Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity.

Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE.

Cancer Immunol Res. 2017 Jul;5(7):516-523. doi: 10.1158/2326-6066.CIR-16-0264. Epub 2017 Jun 15.


Endometrial adenosarcoma in the setting of a germline DICER1 mutation: A case report.

Mullen MM, Divine LM, Hagemann IS, Babb S, Powell MA.

Gynecol Oncol Rep. 2017 Apr 11;20:121-124. doi: 10.1016/j.gore.2017.04.004. eCollection 2017 May.


Osteolipoma of the knee.

Huynh TV, Cipriano CA, Hagemann IS, Friedman MV.

Radiol Case Rep. 2016 Nov 23;12(1):124-129. doi: 10.1016/j.radcr.2016.10.015. eCollection 2017 Mar.


Association of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix.

Tandon B, Hagemann IS, Maluf HM, Pfeifer JD, Al-Kateb H.

Int J Gynecol Pathol. 2017 Nov;36(6):593-599. doi: 10.1097/PGP.0000000000000365.


Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.

Lee PJ, Yoo NS, Hagemann IS, Pfeifer JD, Cottrell CE, Abel HJ, Duncavage EJ.

Exp Mol Pathol. 2017 Feb;102(1):156-161. doi: 10.1016/j.yexmp.2017.01.012. Epub 2017 Jan 14.


Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma.

Li J, Xing X, Li D, Zhang B, Mutch DG, Hagemann IS, Wang T.

Neoplasia. 2017 Feb;19(2):100-111. doi: 10.1016/j.neo.2016.12.009. Epub 2017 Jan 12.


AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer.

Divine LM, Nguyen MR, Meller E, Desai RA, Arif B, Rankin EB, Bligard KH, Meyerson C, Hagemann IS, Massad M, Thaker PH, Hagemann AR, McCourt CK, Powell MA, Mutch DG, Fuh KC.

Oncotarget. 2016 Nov 22;7(47):77291-77305. doi: 10.18632/oncotarget.12637.


Molecular Testing in Breast Cancer: A Guide to Current Practices.

Hagemann IS.

Arch Pathol Lab Med. 2016 Aug;140(8):815-24. doi: 10.5858/arpa.2016-0051-RA. Review.


A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia.

Lu C, Riedell P, Miller CA, Hagemann IS, Westervelt P, Ozenberger BA, O'Laughlin M, Magrini V, Demeter RT, Duncavage EJ, Griffith M, Griffith OL, Wartman LD.

Cold Spring Harb Mol Case Stud. 2016 Jan;2(1):a000687. doi: 10.1101/mcs.a000687.


Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach.

Hagemann IS, O'Neill PK, Erill I, Pfeifer JD.

Cancer Genet. 2015 Sep;208(9):441-7. doi: 10.1016/j.cancergen.2015.05.030. Epub 2015 May 29.


T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides.

Sufficool KE, Lockwood CM, Abel HJ, Hagemann IS, Schumacher JA, Kelley TW, Duncavage EJ.

J Am Acad Dermatol. 2015 Aug;73(2):228-36.e2. doi: 10.1016/j.jaad.2015.04.030. Epub 2015 Jun 3.


Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.

Chernock RD, Hagemann IS.

Am J Clin Pathol. 2015 Jun;143(6):768-77. doi: 10.1309/AJCPHWACTTUYJ7DD. Review.


Optimal sampling of grossly normal omentum in staging of gynecologic malignancies.

Skala SL, Hagemann IS.

Int J Gynecol Pathol. 2015 May;34(3):281-7. doi: 10.1097/PGP.0000000000000148.


The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

Clin Cancer Res. 2015 Jun 15;21(12):2840-50. doi: 10.1158/1078-0432.CCR-14-2777. Epub 2015 Feb 23.


Seminoma presenting as renal mass, inferior vena caval thrombus, and regressed testicular mass.

Raup VT, Johnson MH, Weese JR, Hagemann IS, Marshall SD, Brandes SB.

Case Rep Urol. 2015;2015:835962. doi: 10.1155/2015/835962. Epub 2015 Jan 29.


The Cancer Genomics Resource List 2014.

Zutter MM, Bloom KJ, Cheng L, Hagemann IS, Kaufman JH, Krasinskas AM, Lazar AJ, Leonard DG, Lindeman NI, Moyer AM, Nikiforova MN, Nowak JA, Pfeifer JD, Sepulveda AR, Willis JE, Yohe SL.

Arch Pathol Lab Med. 2015 Aug;139(8):989-1008. doi: 10.5858/arpa.2014-0330-CP. Epub 2014 Dec 1.


Clinical next-generation sequencing in patients with non-small cell lung cancer.

Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R.

Cancer. 2015 Feb 15;121(4):631-9. doi: 10.1002/cncr.29089. Epub 2014 Oct 24.


Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers.

Zhang B, Xing X, Li J, Lowdon RF, Zhou Y, Lin N, Zhang B, Sundaram V, Chiappinelli KB, Hagemann IS, Mutch DG, Goodfellow PJ, Wang T.

BMC Genomics. 2014 Oct 6;15:868. doi: 10.1186/1471-2164-15-868.


Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.

Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G.

Nat Med. 2014 Jun;20(6):607-15. doi: 10.1038/nm.3541. Epub 2014 May 4.


Diagnostic utility of targeted next-generation sequencing in problematic cases.

Sehn JK, Hagemann IS, Pfeifer JD, Cottrell CE, Lockwood CM.

Am J Surg Pathol. 2014 Apr;38(4):534-41. doi: 10.1097/PAS.0000000000000161.


Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.

Hagemann IS, Govindan R, Javidan-Nejad C, Pfeifer JD, Cottrell CE.

J Thorac Oncol. 2014 Feb;9(2):e12-6. doi: 10.1097/JTO.0b013e3182a7d22e.


Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy.

Hagemann IS, Cottrell CE, Lockwood CM.

Cancer Genet. 2013 Dec;206(12):420-31. doi: 10.1016/j.cancergen.2013.11.003. Epub 2013 Nov 22. Review.


Validation of a next-generation sequencing assay for clinical molecular oncology.

Cottrell CE, Al-Kateb H, Bredemeyer AJ, Duncavage EJ, Spencer DH, Abel HJ, Lockwood CM, Hagemann IS, O'Guin SM, Burcea LC, Sawyer CS, Oschwald DM, Stratman JL, Sher DA, Johnson MR, Brown JT, Cliften PF, George B, McIntosh LD, Shrivastava S, Nguyen TT, Payton JE, Watson MA, Crosby SD, Head RD, Mitra RD, Nagarajan R, Kulkarni S, Seibert K, Virgin HW 4th, Milbrandt J, Pfeifer JD.

J Mol Diagn. 2014 Jan;16(1):89-105. doi: 10.1016/j.jmoldx.2013.10.002. Epub 2013 Nov 6.


Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.

Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ Jr.

PLoS One. 2012;7(11):e49829. doi: 10.1371/journal.pone.0049829. Epub 2012 Nov 26.


Mammaglobin expression in gynecologic adenocarcinomas.

Hagemann IS, Pfeifer JD, Cao D.

Hum Pathol. 2013 Apr;44(4):628-35. doi: 10.1016/j.humpath.2012.07.013. Epub 2012 Oct 17.


Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible.

Zaino RJ, Abendroth C, Yemelyanova A, Oliva E, Lim D, Soslow R, DeLair D, Hagemann IS, Montone K, Zhu J.

Gynecol Oncol. 2013 Jan;128(1):83-87. doi: 10.1016/j.ygyno.2012.09.035. Epub 2012 Oct 10.


Aberrant connexin 43 and 26 expression in cervical dysplasia.

Hagemann IS, Pasha TL, Roberts SA, Yum SW, Zhang PJ.

Anal Quant Cytol Histol. 2012 Feb;34(1):28-40.


Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.

Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr.

Mol Ther. 2012 Mar;20(3):633-43. doi: 10.1038/mt.2011.256. Epub 2011 Nov 29.


Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G.

Gynecol Oncol. 2012 Feb;124(2):192-8. doi: 10.1016/j.ygyno.2011.09.039. Epub 2011 Oct 29.


Risk of occult malignancy in morcellated hysterectomy: a case series.

Hagemann IS, Hagemann AR, LiVolsi VA, Montone KT, Chu CS.

Int J Gynecol Pathol. 2011 Sep;30(5):476-83. doi: 10.1097/PGP.0b013e3182107ecf.


Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.

Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ Jr, Feldman MD, Coukos G.

Cancer Biol Ther. 2011 Aug 15;12(4):367-77. Epub 2011 Aug 15.


Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.

Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Gimotty PA, Coukos G.

Cancer Biol Ther. 2011 Aug 15;12(4):357-66. Epub 2011 Aug 15.


Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G.

Nature. 2011 Jul 13;475(7355):226-30. doi: 10.1038/nature10169.


Benjamin Franklin's risk factors for gout and stones: from genes and diet to possible lead poisoning.

Finger S, Hagemann IS.

Proc Am Philos Soc. 2008 Jun;152(2):189-206.


A retrospective comparison of 2 methods of intraoperative margin evaluation during partial nephrectomy.

Hagemann IS, Lewis JS Jr.

J Urol. 2009 Feb;181(2):500-5. doi: 10.1016/j.juro.2008.10.020. Epub 2008 Dec 13.


Basaloid squamous cell carcinoma arising in [corrected] the renal pelvis.

Hagemann IS, Lu J, Lewis JS Jr.

Int J Surg Pathol. 2008 Apr;16(2):199-201. doi: 10.1177/1066896907306197. Erratum in: Int J Surg Pathol.2008 Jul;16(3);355.


A careful look at community CPR training.

Hagemann IS.

Mo Med. 2007 Nov-Dec;104(6):481-4. Review. No abstract available.


Structure of the complement factor 5a receptor-ligand complex studied by disulfide trapping and molecular modeling.

Hagemann IS, Miller DL, Klco JM, Nikiforovich GV, Baranski TJ.

J Biol Chem. 2008 Mar 21;283(12):7763-75. doi: 10.1074/jbc.M709467200. Epub 2008 Jan 14.


E2F8 is a nonreceptor activator of heterotrimeric G proteins.

Hagemann IS, Narzinski KD, Baranski TJ.

J Mol Signal. 2007 Mar 30;2:3.

Supplemental Content

Loading ...
Support Center